Osteopore Lands $520K Upfront as China Partner Commits to Bone Implant Rollout
Osteopore receives AUD 520,000 upfront fee from Majeton
Osteopore Limited (ASX: OSX) has received an upfront dossier fee of RMB 2.5 million (~AUD 520,000) from its exclusive partner Majeton, as part of the key terms for the commercialisation of its innovative dental, orthodontic, and maxillofacial products in China, Hong Kong, and Macau. The payment follows the exclusive collaboration announced on 16 January 2026.
The cash receipt demonstrates Majeton’s commitment to the collaboration and provides Osteopore with near-term revenue whilst the parties work towards regulatory approvals across the Greater China region.
Partnership milestones extend to 2034
Osteopore and Majeton are working to achieve key milestones related to product listing processes and approvals in China, Hong Kong, and Macau, with various timelines from 30 June 2027 to 1 January 2034.
| Territory | Product Focus | Timeline Range |
|---|---|---|
| China, Hong Kong, Macau | Dental, orthodontic, maxillofacial | 30 June 2027 – 1 January 2034 |
Osteopore will continue to keep the market apprised of major developments in this commercial collaboration.
When big ASX news breaks, our subscribers know first
What is bioresorbable bone technology?
Osteopore’s patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material. Unlike traditional permanent implants, these scaffolds naturally dissolve over time, allowing healthy bone tissue to regenerate in their place. This is the technology Majeton will commercialise across the Greater China region under the exclusive partnership.
Key technology benefits include:
- Natural dissolution: Scaffolds made from a proprietary polymer that naturally dissolves over time, eliminating the need for removal surgery
- Reduced complications: Significantly reduces post-surgery complications commonly associated with permanent bone implants
- Proprietary manufacturing: Osteopore’s 3D printing technique is unique and patent-protected, creating a competitive moat in the regenerative medicine sector
- Targeted applications: Designed specifically for dental, orthodontic, and maxillofacial surgery where bone regeneration is critical
The technology addresses a significant unmet clinical need in procedures where permanent implants may cause long-term complications or require secondary surgeries for removal.
The next major ASX story will hit our subscribers first
Why China matters for Osteopore’s growth trajectory
The Greater China region represents one of the world’s largest medical device markets, making the Majeton partnership strategically valuable for Osteopore’s international expansion. The collaboration structure provides market access whilst Osteopore retains manufacturing and intellectual property control.
Strategic benefits of the partnership include:
- Market access: The partnership opens access to China, Hong Kong, and Macau through an established local partner
- Exclusive territory rights: The partnership grants Majeton exclusive commercialisation rights across the Greater China region, ensuring focused market development
- Long-term revenue potential: Successful regulatory approvals could unlock substantial recurring revenue streams from product sales in a high-growth medical device market
The AUD 520,000 upfront payment demonstrates Majeton’s financial commitment to the collaboration.
Next steps for investors to watch
Investors should monitor announcements regarding product listing progress in China, Hong Kong, and Macau as Osteopore and Majeton work through the regulatory milestone schedule extending to 2034. The company has committed to keeping the market informed of major developments in this commercial collaboration.
Key catalysts ahead include regulatory submission outcomes, approval confirmations, and any commercial launch timelines once product listings are secured across the Greater China territories.
Want the Next Healthcare Breakout in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get real-time alerts and expert coverage the moment market-moving announcements break.